Belluscura Share Discussion Threads

[babbler] 13/2/2024 07:15

Great news .

[mr.oz] 09/2/2024 12:04

Well worth the read, update out last night

[mr.oz] 09/2/2024 09:54

Hopefully, a line can be drawn.
Need a prod update next.

[chester9] 24/1/2024 16:23

It's more a show of the Tek managements incompetence. Lucyd failing but they have cash so Tek got a loan. Bell getting cash through the alternate route to cash raise but Tek selling Bell at share price low. All now on Microsalt which I have tried. Taste is good but it's a bit like talc powder to put on. Bell better off without Tek.

[teamrilex] 24/1/2024 15:23

Is this company capable of delivering any good news?

[dr biotech] 24/1/2024 13:30

Its not a great show of confidence is it? TEK dumping a shedload at 16.5p You'd think they would know more than most about whats going on here. Perhaps if Brummy does another interview he can ask about the actual number of units sold.

[maytrees] 24/1/2024 08:18

Good morning
Possibly BELL share price has been held down recently by TEK selling 3.5m to fund raise?

[dr biotech] 19/1/2024 18:52

Two years ago I said that this was over valued (and multiple times since). Given their track record I'd value this at cash.

No surprise they have had to offer more paper.


Dr Biotech - 22 Feb 2022 - 10:08:29 - 224 of 596 BELLUSCURA - Enrichment through oxygen concentrators - BELL
£90m enterprise value for a company that has approx annualised sales of £1m and makes a substantial loss?

Going to have to get a lot of things right.

[owenski] 19/1/2024 14:00

"31p by end of month"...... Massive lols to that, if ZM comments on tea leaf readings, expect the opposite to occur.

[jaknife] 19/1/2024 13:49

The offer for TMTA has been re-priced again, now it's a one for one:

[mr.oz] 03/1/2024 12:15

5 mins in , talks about BELL
TP 31p by end of month, if not sooner and then 43p a month later best case.

[mr.oz] 03/1/2024 09:53

Any TA experts out there?
Could be interesting

[maytrees] 02/1/2024 09:50

Happy new year

Dead cat bounce or good news I wonder?

[dr biotech] 20/12/2023 10:35

They are offering a $500 discount on their website.


I've seen quite a few people about with portable generators, but all seem to be pretty ill - perhaps not quite end of life but certainly wheelchair bound or restricted mobility. Not out hiking.

May be a buy soon, but I'm going to wait for actual numbers.

[mr.oz] 20/12/2023 09:46

Owenski
Where do you get your figs from?

DISCOV-R™ were selling for $2300,that's according to 15mill revenue expected from 6500 units

Now $3000 per unit

It's a price rise

[dr biotech] 20/12/2023 08:56

Noticeable lack of numbers in the trading statement

[owenski] 20/12/2023 08:52

Currently, they're offering a $500 dollar price reduction sale on existing Ox-Gens, that sounds like they need to drum up sales.

So what's happened to the Discov-R sales, that was already touted as a game changer and is currently in production at their US in house facility.

Discov-R was supposed to already be delivering game changing sales volumes. Sounds like that's just not selling in the volumes the market was led to believe in.

Now they're waiting to launch the next thing - Xplor - to save the company. They're relying on a China deal when they already have a product and a market in the US, it seems that the uptake of the current Discov-r just aint occurring, so why should Xplor be any different.

Not convinced their sales are going to be what the company has led investors to believe. The share price chart tell you clearly what the market thinks.

I'm just not that convinced in these end markets either. How many people has anyone ever seen out and about actually with a portable Oxy bottle in the first place anyway. I've seen two in my life. Can't believe they're all stuck at home waiting to get out and about and cleaning the car in the driveway. Not everyone with COPD uses extra oxygen facilities either. Just saying, not convinced in the size or uptake of these so called end markets, BELL might well have a disruptive product, but it could well be a much smaller niche market.

I've met the management and like them, so I wish the company well and would like to have invested at one point, but it looks like this will just be staying on a watch list.

[brummy_git] 20/12/2023 07:45

You can't keep a great business down.

After delays wrt its pending £5.8m #TMTA acquisition, Belluscura said today that China (ie world's largest COPD market) had approved its leading XPLOR portable oxygen concentrator.

All the details here.

[brummy_git] 12/12/2023 07:36

Strategically important, new regulatory approval from Singapore received today for leading portable oxygen concentrator firm Belluscura.

All the details here.

[dr biotech] 06/12/2023 10:07

Can TMTA back out? Looks like they could get less than the cash value

[hedgehog 100] 25/10/2023 19:12

Dr. Biotech,

If TMTA didn't think that BELL was a good investment, then why would they (in effect) be investing here?

Obviously with the BELL share price falling this month, the deal with TMTA has been changed to reflect that.

It just goes to show that 'cash is king', especially at the moment.

TMTA has it, & BELL wants it, which puts TMTA in the stronger bargaining position.

Remember that the deal has to be approved by TMTA shareholders, and with the TMTA share price (at just 17p) trading at less than its cash per share, it's understandable that they would look for 'better' terms.

And a wider issue is: what is the outlook for future new issues in the nearer term?

Judging from TMTA's choice of BELL, there is nothing better in the offing at present (that has't already been accounted for by another shell, at least) ...

The backdrop is that UK penny shares as a whole are depressed at the moment ... but that can change very quickly (especially for already listed shares).

Interest rates won't stay this high for ever, so I think that now is the time to be picking up bargains, to ride the likely recovery.

If you look back to late 2009, during the credit crunch, some of the bargains then now look absolutely mouth-watering.

Which was reflected in the huge, multibagging gains which they subsequently recorded, some of which were pretty quick, relatively speaking.

Now is, I believe, such as time.

And as such, now is the time to, in effect, 'get rich'.

[dr biotech] 25/10/2023 18:14

So BELL have again exceeded expectations, showing that the swift appointment of distributors in 2021 was no flash in the pan.

When did they previously exceed expectations?

Anyone can sign up distributors - there are hundreds of companies that will just put your product on to a website - getting ones that will go out and sell it is another matter.

Often signing up too many will result in fewer sales. Those that go out and sell don't want to be undercut by those that just carry the product and offer it cheaply.

TMTA get 10% more - do they have any trading info? doesn't bode particularly well, though has to be said just about everything is down this month.

[hedgehog 100] 25/10/2023 16:28

The TMTA acquisition still looks a good deal for BELL.

Remember that TMTA's £4.7M. cash is in effect worth a lot more than that to BELL, because of the frequent high cost of raising capital through placings, and possible significant discounts required.

Shells like TMTA also tend to have a very 'sticky' shareholders base, probably more likely to add to their holdings than sell.
Whereas many small company placees may simply be 'stagging' the issue.

There is also the considerable bonus of having TMTA's very impressive 'shellmeisters' on board BELL.


Here are a couple of recent IPOs with placings of several million pounds each, which each paid well over a million pounds in costs:-

From the Tan Delta Systems (TAND) Admission Document, 11 August 2023:-

"Gross proceeds of the Placing receivable by the Company £6.0 million
Estimated net proceeds of the Placing receivable by the Company(2) £4.8 million"

"(2) After deduction of estimated commissions, fees and expenses (excluding VAT) of the Fundraising and Admission payable by the Company of approximately £1.2 million."



From the Tribe Technology (TRYB) Admission Document, 30 August 2023:-

"Gross proceeds of the Fundraising £4,500,000
(excluding the Retail Subscription Shares)
Estimated net proceeds of the Fundraising2 £3,200,000"

"2 After deduction of estimated commissions, fees and expenses payable by the Group of approximately £1,300,000."

[hedgehog 100] 25/10/2023 11:45

Date Time Source Headline Symbol Company
25/10/2023 07:00 UK Regulatory (RNS & others) Belluscura PLC Statement regarding possible offer LSE:BELL Belluscura Plc

"Statement regarding possible offer for TMT Acquisition plc

The boards of Belluscura plc (AIM: BELL) and TMT Acquisition plc ("TMT Acquisition") announced on 3 October 2023 that they had reached agreement on the key terms of a possible share for share offer for TMT Acquisition by Belluscura (the "Possible Offer").

Both companies have completed confirmatory due diligence and expect to be in a position to announce a firm offer shortly, and by not later than 5.00 p.m. on 31 October 2023. The terms of the Possible Offer have been revised and will now comprise the issuance of 3 new ordinary shares of Belluscura ("Belluscura Shares") in exchange for every 4 ordinary shares of TMT Acquisition ("TMT Acquisition Shares") equaling 20,625,000 Belluscura Shares (the "Revised Exchange Ratio").

The Revised Exchange Ratio would imply a valuation of 20.25 pence for each TMT Acquisition Share based upon the Belluscura closing middle market price of 27.0p on 24 October 2023, being the last practicable date prior to the announcement of the Revised Possible Offer (the "Revised Possible Offer Terms").

Accordingly, on the basis of the Revised Exchange Ratio, the Revised Possible Offer Terms will imply a total valuation of GBP5.57 million for TMT Acquisition, representing a premium of approximately:

-- 19.12 % to the closing price of a TMT Acquisition Share of 17.0p on 24 October 2023, being the last business day before this announcement; and

-- 14.30 % to the TMT Acquisition three-month volume weighted average price for the period ending 24 October 2023, being the last business day before this announcement.

The independent director of TMT Acquisition, Paul Tuson (the "Independent TMT Acquisition Director"), has reconfirmed to Belluscura that, should a firm offer be made on the Revised Possible Offer Terms (as outlined above), the Independent TMT Acquisition Director is minded to recommend it to TMT Acquisition shareholders.

Any announcement by Belluscura of a firm intention to make an offer for TMT Acquisition remains subject to the satisfaction or waiver (by Belluscura) of a number of customary pre-conditions, including, inter alia, completion of confirmatory due diligence, agreement of the detailed terms of the Possible Offer and a recommendation from the Independent TMT Acquisition Director. ..."




So, improved terms for TMTA, to reflect the dip in the BELL share price - these were probably necessary to get the deal approved by TMTA.

Previously, the provisional arrangement was 15 BELL shares for every 22 TMTA shares; now the intended arrangement will equate to 16.5 BELL shares for every 22 TMTA shares: i.e. TMTA shareholders should get 10% more than previously.

The current BELL share price is 26.5p (25p - 28p): which based on 3 BELL shares for every 4 TMTA shares equates to 19.875p (18.75p - 21p) TMTA.

But TMTA is currently 17p (16p - 18p), giving a reasonably attractive arbitrage opportunity here again, especially if you can get inside the headline spreads.